HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition
about
Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyAlteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinomaImmunotherapy as a Potential Treatment for Chordoma: a Review.Peripheral blood cells inform on the presence of breast cancer: a population-based case-control studyImpact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults.Cancer genome sequencing and its implications for personalized cancer vaccines.Contagious cancer: lessons from the devil and the dog.The immunosuppressive molecule HLA-G and its clinical implications.Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.Cancer treatment and the KIR-HLA system: an overview.HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer.HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationPersonalized cancer vaccines: Targeting the cancer mutanome.Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy.Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.Introductory Chapter: A Brief Overview on Natural Killer Cells
P2860
Q26771449-F4E51F5B-6035-4B30-AA1C-6FFE3F8FB40EQ28265651-8A93408F-550F-475B-A790-642BA5EB8A58Q33276143-6F224119-34CB-4575-A94E-0AAF18132CA6Q34782137-ED6FE503-0633-4F40-B90C-C57FD815E2F9Q36737701-F8097F81-7633-49FF-8EE7-10EC916F24ACQ37148184-4DA9A3DC-897F-4733-8ED6-A8E50D4B3F37Q37989886-74C2C07E-2293-49C4-B8EF-905A26D3FC0CQ38005743-777A712E-DB17-4A3F-81A5-7D05B8CC8B7FQ38912084-BB9440EF-505C-442C-BA43-D1FCF1150E04Q38962024-F87BB2B5-8E57-44C5-85C3-A9799A0B4143Q39131056-4319BFC4-BD59-4517-A1B2-503D5F832BB5Q39201713-5DB923CB-64B9-43CC-953A-9D8697FBD877Q39486461-A0C376C0-30F4-4DAA-9F2B-8C864685B04EQ42702294-A2226E69-0E89-45A2-BA55-E3B352452D36Q49956120-14791068-8E70-42C6-BF41-19194106C0D4Q51219083-E5D8E3DD-10D8-4B2F-B91A-538FBB3918AEQ53083279-59DA75A4-09AC-419F-B0A2-2807B3C9F528Q59275329-AEFB5E6D-321A-4B0A-B442-DD3D2B3A6970
P2860
HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
HLA antigen and NK cell activa ...... a story of loss or acquisition
@ast
HLA antigen and NK cell activa ...... a story of loss or acquisition
@en
type
label
HLA antigen and NK cell activa ...... a story of loss or acquisition
@ast
HLA antigen and NK cell activa ...... a story of loss or acquisition
@en
prefLabel
HLA antigen and NK cell activa ...... a story of loss or acquisition
@ast
HLA antigen and NK cell activa ...... a story of loss or acquisition
@en
P2860
P1476
HLA antigen and NK cell activa ...... a story of loss or acquisition
@en
P2093
Michael Campoli
Soldano Ferrone
P2860
P2888
P304
P356
10.1007/S00281-011-0270-Z
P577
2011-04-28T00:00:00Z